

Supplemental Table 1. Baseline Characteristics across the PR interval, heart rate and left ventricular hypertrophy

	PR Interval		Heart Rate (HR)			LVH by ECG	
	< 200 ms	≥ 200 ms	< 60 bpm	60-90 bpm	≥ 90 bpm	Absent	Present
Number of Participants	3045	542	1196	2285	105	3272	315
Demographics							
Age (years)±SD	57±11	62±10	60±11	58±11	52±13	58±11	60±10
Female n(%)	1432(47)	191 (35)	490 (41)	1071 (47)	62 (59)	1410 (43)	213 (68)
Race							
White n(%)	1286 (42)	204 (38)	575 (48)	878 (38)	37 (35)	1433 (44)	57 (18)
Black n(%)	1203 (40)	279 (52)	446 (37)	988 (43)	48 (46)	1275 (39)	207 (66)
Hispanic n(%)	432 (14)	38 (7)	128 (11)	325 (14)	17 (16)	436 (13)	34 (11)
Prevalent Cardiovascular Disease							
Coronary Artery Disease n(%)	594 (20)	175 (32)	311 (26)	434 (19)	24 (23)	665 (20)	104 (33)
Heart Failure n(%)	236 (8)	91 (17)	99 (8)	214 (9)	14 (13)	260 (8)	67 (21)
Peripheral Vascular Disease n(%)	195 (6)	40 (7)	60 (5)	166 (7)	9 (9)	215 (7)	20 (6)
Stroke n (%)	287 (9)	67 (12)	129 (11)	214 (9)	11 (11)	305 (9)	49 (16)
Cardiovascular Disease Risk Factors							
Systolic BP (mmHg)±SD	129±22	129±22	127±22	129±22	131±24	127±22	141±24
Diastolic BP (mmHg)±SD	72±13	70±13	70±13	72±13	75±13	71±13	75±16
Hypertension n(%)	2591 (85)	493 (91)	1019 (85)	1980 (87)	85 (81)	2786 (85)	298 (95)
Diabetes n(%)	1447 (48)	283 (52)	445 (37)	1208 (53)	77 (73)	1562 (48)	168 (53)
Body mass index (kg/m ²)±SD	31.7±7.8	33.5±7.3	30.9±7.0	32.4±8.0	34.8±10	31.9±7.8	32.4±7.8
Smoking status n(%)							
Current	402 (13)	65 (12)	132 (11)	317 (14)	18 (17)	423 (13)	44 (14)
Past	1238 (41)	252 (47)	523 (44)	926 (41)	41 (39)	1369 (42)	121 (38)
Never	1405 (46)	225 (42)	541 (45)	1043 (46)	46 (44)	1480 (45)	150 (48)
Total cholesterol (mg/dL)±SD	185±46	178±39	181±42	186±47	187±51	184±45	188±45
HDL (mg/dL)±SD	48±16	45±14	48±16	47±15	46±14	47±15	50±19
LDL (mg/dL)±SD	104±36	100±32	102±35	104±36	101±37	103±36	104±35
Triglycerides (mg/dL)±SD	158±121	157±105	144±88	164±127	192±199	158±118	163±122
Echocardiographic Variables							

LV mass index (g/m ^{2.7}) ±SD	105±25	115±28	107±24	106±27	106±25	105±25	123±32
LV ejection fraction (%)±SD	55±8	52±10	55±8	54±9	52±10	55±8	52±11
LV ejection fraction categories							
<35%, n(%)	80 (3)	30 (7)	20 (2)	84 (4)	6 (8)	81 (3)	29 (11)
35-50%, n(%)	401 (16)	102 (23)	163 (16)	324 (17)	16 (21)	453 (17)	50 (20)
>50%, n(%)	2057 (81)	319 (71)	819 (82)	1501 (79)	56 (72)	2200 (81)	176 (69)
Kidney Function							
eGFR (mL/min/1.73m ²)±SD	45±17	44±16	47±18	44±17	44±17	45±17	41±15
eGFR categories (mL/min/1.73m ²)							
<15 n(%)	11 (0.4)	0 (0)	2 (0.2)	8 (0.3)	1 (1)	9 (0.3)	2 (0.6)
15-30 n(%)	606 (20)	117 (22)	225 (19)	473 (21)	25 (24)	647 (20)	76 (24)
30-60 n(%)	1856 (61)	346 (64)	714 (60)	1427 (62)	61 (58)	2005 (61)	197 (63)
60-90 n(%)	526 (17)	75 (14)	230 (19)	354 (16)	17 (16)	562 (17)	39 (12)
≥90 n(%)	46 (2)	4 (1)	25 (2)	24 (1)	1 (1)	49 (2)	1 (0.3)
Cystatin C (mg/L)±SD	1.51±0.55	1.54±0.53	1.46±0.54	1.54±0.55	1.64±0.60	1.50±0.54	1.61±0.56
Proteinuria (mg/24H)	190	170	130	230	300	170	310
Median [IQR]	[70-960]	[70-720]	[70-580]	[80-1100]	[100-2030]	[70-880]	[100-1350]
Serum Measures							
Serum Calcium (mg/dL)±SD	9.2±0.5	9.2±0.5	9.2±0.5	9.2±0.5	9.2±0.6	9.2±0.5	9.2±0.5
Serum Phosphate (mg/dL)±SD	3.7±0.7	3.7±0.7	3.7±0.6	3.8±0.7	3.9±0.7	3.7±0.7	3.9±0.7
Serum Potassium (mmol/L)±SD	4.4±0.5	4.3±0.6	4.3±0.5	4.4±0.5	4.4±0.6	4.4±0.5	4.2±0.5
Serum Albumin (g/dL)±SD	3.9±0.5	4.0±0.4	4.0±0.4	3.9±0.5	3.9±0.6	3.9±0.5	3.9±0.5
Hemoglobin (g/dL)±SD	12.6±1.8	12.6±1.6	12.8±1.6	12.5±1.8	12.0±1.7	12.6±1.8	12.3±1.8
Medications n(%)							
Aspirin	1271 (42)	278 (52)	551 (46)	961 (42)	37 (36)	1398 (43)	151 (48)
Beta Blockers	1409 (47)	341 (63)	726 (61)	996 (44)	28 (27)	1551 (48)	199 (64)
Calcium Channel Blockers	1163 (39)	273 (51)	489 (41)	921 (41)	26 (25)	1263 (39)	173 (55)
Statins	1632 (54)	332 (62)	656 (55)	1249 (55)	59 (57)	1795 (55)	169 (54)

Supplemental Table 2. Association of ECG Metrics and Cardiovascular Death in the Echocardiographic Subgroup

	Categorical			Linear model
PR Interval Adjusted*; HR (95% CI)	PR < 200 ms 1.00 (ref)	PR ≥ 200 ms 1.60 (1.08, 2.35)		Per 10 ms increase 1.05 (1.00, 1.11)
QRS Interval Adjusted*; HR (95% CI)	QRS < 100 ms 1.00 (ref)	QRS 100-119 ms 1.61 (1.07, 2.43)	QRS ≥ 120 ms 2.06 (1.24, 3.42)	Per 10 ms increase 1.11 (1.02, 1.21)
QT_c Interval Adjusted*; HR (95% CI)	QT_c < 450 M / 460 W ms 1.00 (ref)	QT_c ≥ 450 M / 460 W 1.28 (0.79, 2.09)		Per 10 ms increase 1.02 (0.96, 1.09)
Heart Rate (HR) Adjusted*; HR (95% CI)	HR < 60 bpm 1.00 (ref)	HR 60-90 bpm 1.49 (1.00, 2.23)	HR ≥ 90 bpm 2.60 (0.86, 7.85)	RR interval per 50 ms decrease 1.09 (1.02, 1.16)
LVH Adjusted*; HR (95% CI)	Absent 1.00 (ref)	Present 0.79 (0.47, 1.33)		Per 10 mm 0.99 (0.96, 1.01)

*The adjusted analysis included the following covariates: age, sex, race, clinical site, history of cardiovascular disease (coronary artery disease, congestive heart failure, peripheral vascular disease, and stroke), systolic blood pressure, diastolic blood pressure, total cholesterol, high density lipoprotein, body mass index, current smoking status, diabetes, estimated GFR, log (urine total protein excretion), serum calcium, serum phosphate, serum potassium, medication use (beta blockers, calcium channel blockers, and statin), left ventricular mass index and left ventricular ejection fraction. In addition, with the exception of the assessed ECG parameter, the adjusted analysis included the other 4 metrics.